2014
Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base
Moreno AC, Morgensztern D, Boffa DJ, Decker RH, Yu JB, Detterbeck FC, Wang Z, Rose MG, Kim AW. Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base. The Annals Of Thoracic Surgery 2014, 97: 1149-1155. PMID: 24582051, DOI: 10.1016/j.athoracsur.2013.12.045.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseCell lung cancerOverall survivalPostoperative radiotherapyLung cancerRadiation therapyLymph Node-positive Non-small Cell Lung CancerNode-positive non-small cell lung cancerLarge non-small cell lung cancersAdvanced non-small cell lung cancerPositive non-small cell lung cancerFive-year overall survivalHilar lymph node involvementPrimary surgical therapyPrimary surgical treatmentLymph node involvementKaplan-Meier methodSurvival of patientsCox regression modelLog-rank testAdjuvant chemoradiationAdjuvant fashionAdvanced diseaseNeoadjuvant chemoradiation
2012
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA 2012, 307: 2418-2429. PMID: 22610500, PMCID: PMC3709596, DOI: 10.1001/jama.2012.5521.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer mortalityLung cancerLDCT screeningCancer deathCancer mortalityEffect of LDCTSystematic reviewNational Lung Screening TrialEvidence-based clinical guidelinesFrequency of followLung cancer deathsLung cancer screeningRisk of deathPotential harmAdvanced diseaseCause mortalityCohort studyMost patientsSecondary outcomesMajor complicationsPrimary outcomeRandomized studyRandomized trialsCT screening
2006
Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology 2006, 20: 899-905; discussion 905-8, 913. PMID: 16922260.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeInoperable early stageSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalMinority of patientsRadiotherapy dose escalationDefinitive treatment optionEarly-stage patientsOverall survival dataNew treatment modalitiesMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityEvaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy. Oncology 2006, 20: 727-36. PMID: 16841796.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalEarly-stage patientsMinority of patientsRadiotherapy dose escalationDefinitive treatment optionOverall survival dataMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityTreatment optionsRadiofrequency ablation